Satsuma Pharmaceuticals, which was spun out of Shin Nippon Biomedical Laboratories (SNBL) over 6 years ago to develop an intranasal dry powder formulation of dihydroergotamine, has announced that it will now be acquired by SNBL. Satsuma recently said that it had submitted an NDA for STS101 DHE nasal powder for the treatment of migraine despite the failure of the Phase … [Read more...] about Satsuma Pharmaceuticals and its STS101 DHE nasal powder to be reacquired by SNBL
Business
Aer Therapeutics closes $36 million financing to support development of AER-01 inhaled mucolytic for COPD
University of California, San Francisco spinout Aer Therapeutics has closed a $36 million Series A financing, with funds intended to support development of the company's AER-01 inhaled mucolytic for the treatment of COPD, the company said. According to the announcement, AER-01 is a thiol-saccharide designed to dissolve mucus plugs and was developed at UCSF in … [Read more...] about Aer Therapeutics closes $36 million financing to support development of AER-01 inhaled mucolytic for COPD
Tiziana says it will develop intranasal foralumab for the treatment of long COVID
Tiziana Life Sciences has announced that the company will develop intranasal foralumab for the treatment of long COVID. In August 2021, Tiziana announced positive results from a pilot study of intranasal foralumab in mild-to-moderate COVID. The nasal formulation is currently in development for the treatment of non-active secondary progressive multiple sclerosis, and … [Read more...] about Tiziana says it will develop intranasal foralumab for the treatment of long COVID
Evoke gets notice of allowance for additional US patent covering Gimoti metoclopramide nasal spray
According to Evoke Pharma, the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent that will protect the company's Gimoti metaclopramide nasal spray until 2030. The patent (No. 11628150, "Nasal Formulation of Metoclopramide") is expected to be issued on April 18, 2023. Other patents covering Gimoti include Nos. … [Read more...] about Evoke gets notice of allowance for additional US patent covering Gimoti metoclopramide nasal spray
Tiziana to develop intranasal foralumab for hemorrhagic stroke
Tiziana Life Sciences announced that it will advance its intranasal foralumab anti-CD3 monoclonal antibody into clinical development for the treatment of hemorrhagic stroke after a pre-clinical study in a model of intracerebral hemorrhage demonstrated improvement at one month post-dose. The company did not provide details of the study. The company recently … [Read more...] about Tiziana to develop intranasal foralumab for hemorrhagic stroke
GSK gives up exclusive license for use of Liquidia’s PRINT particle technology for inhaled formulations
Liquidia Corporation said that a new agreement will supersede its 2012 license agreement with GSK that gave GSK exclusive rights to develop certain inhaled formulations based on Liquidia's PRINT particle engineering technology. In 2015, GSK exercised an option giving it exclusive worldwide rights to develop PRINT formulations of inhaled therapies, with the exception … [Read more...] about GSK gives up exclusive license for use of Liquidia’s PRINT particle technology for inhaled formulations
PureIMS gets investment to fund development of its Levodopa Cyclops DPI
DPI developer PureIMS announced that it has closed an investment round that included Boost-UP Foundation, CardusoCapital, IMDS Medical Devices, and LinesBridge Pharma Group, with funds intended mostly to support development of a levodopa DPI based on the company's Cyclops pre-filled single use dry powder inhaler. The amount of the new investment was not specified. … [Read more...] about PureIMS gets investment to fund development of its Levodopa Cyclops DPI
Catalent to manufacture HRT’s RiVive naloxone nasal spray
Catalent and Harm Reduction Therapeutics (HRT) announced that they have signed a commercial supply agreement for the manufacture of HRT's RiVive intranasal naloxone. The news comes shortly after HRT said that it would receive an additional $9 million in funding from Purdue Pharma that would be used to prepare for possible commercialization of RiVive. The FDA … [Read more...] about Catalent to manufacture HRT’s RiVive naloxone nasal spray
Harm Reduction Therapeutics to get an additional $9 million from Purdue for development of RiVive naloxone nasal spray
According to Harm Reduction Therapeutics (HRT), the court handling the bankruptcy of Purdue Pharma has approved an additional $9 million in Purdue funds to be used by HRT to prepare for possible commercialization of RiVive intranasal naloxone. HRT notes that "neither Purdue nor any of its creditors will receive any revenues, royalties, or profits associated with … [Read more...] about Harm Reduction Therapeutics to get an additional $9 million from Purdue for development of RiVive naloxone nasal spray
Allermi raises $3.5 million for direct-to-consumer customized nasal spray
US start-up Allermi said that it has raised $3.5 million in a seed round led by Nelstone Ventures for "the world’s first custom approach offered by Allermi that combines and adjusts the doses of multiple clinically-proven medications into one nasal spray bottle to address patients’ specific symptoms." The company says that its nasal spray service is currently … [Read more...] about Allermi raises $3.5 million for direct-to-consumer customized nasal spray